Standout Papers

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controll... 2017 2026 2020 2023 265
  1. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study (2017)
    Désirée van der Heijde, Atul Deodhar et al. Annals of the Rheumatic Diseases
  2. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study (2021)
    Atul Deodhar, Huji Xu et al. Annals of the Rheumatic Diseases
  3. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19 (2024)
    Jennifer Hammond, Robert J. Fountaine et al. New England Journal of Medicine

Immediate Impact

2 from Science/Nature 68 standout
Sub-graph 1 of 22

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Long COVID science, research and policy
2024 Standout
8 intermediate papers

Works of Dona Fleishaker being referenced

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
2024 Standout
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
2021 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Dona Fleishaker 586 298 352 28 873
Chia‐Wei Hsieh 397 326 408 44 1.0k
Heikki Isomäki 559 184 191 15 1.1k
Raquel Cuchacovich 612 297 532 29 979
N. J. GERBER 475 122 264 29 970
Marjatta Sinisalo 129 387 302 32 920
P Casassus 494 158 68 22 1.1k
Angela Midgley 455 188 525 35 1.0k
H V Bashir 424 178 369 32 874
Ιωάννα Μαρίνου 317 61 271 33 948
John P. Leddy 168 314 355 34 1.1k

All Works

Loading papers...

Rankless by CCL
2026